Asset Details
Do you wish to reserve the book?
The Ethics of the “Right-to-Try” Movement in an Era of Regulatory Flux
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Ethics of the “Right-to-Try” Movement in an Era of Regulatory Flux
Do you wish to request the book?
The Ethics of the “Right-to-Try” Movement in an Era of Regulatory Flux
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Ethics of the “Right-to-Try” Movement in an Era of Regulatory Flux
2025
Overview
The Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 signed on May 30, 2018 under President Trump has been championed by patient advocacy groups as a victory for individuals with life threatening illnesses willing to undergo experimental treatment. The act is not a novel idea, but rather a nuanced result of the previous attempts to challenge the US Food and Drug Administration’s (FDA) authority on drug approval and distribution. Currently, right-to-try programs coexist with an already existing expanded access program run by the FDA. The difference is that right-to-try requests eliminate FDA guidance and authorization. The objectives of this study are to review prior historical challenges to the FDA and how they eventually influenced right-to-try movements, examine the law itself and its arguments written by advocates and critics, discuss how its implications fit into the current climate of regulatory flux, and propose the impacts it has on influencing patient care and the scientific process.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Compassionate Use Trials - ethics
/ Compassionate Use Trials - legislation & jurisprudence
/ Drug Approval - legislation & jurisprudence
/ Drug Safety and Pharmacovigilance
/ Drugs
/ Humans
/ Medicine
/ Patients
/ Pharmacy
/ Review
/ Success
/ United States Food and Drug Administration - legislation & jurisprudence
